NCT06012279View on ClinicalTrials.gov

Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)

PHASE4CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

February 26, 2024

Conditions
Acute Heart Failure
Interventions
DRUG

Dapagliflozin 10mg Tab

Dapagliflozin is a drug that works through inhibition of sodium glucose transporter-2 resulting in glucosuria.

Trial Locations (2)

11562

Kasr Al-Ainy Medical School, Cairo

Unknown

Aswan Heart Centre, Aswān

All Listed Sponsors
collaborator

Aswan Heart Centre

OTHER

lead

Cairo University

OTHER

NCT06012279 - Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF) | Biotech Hunter | Biotech Hunter